Sirolimus, Tacrolimus, and Low-Dose Methotrexate as Graft-versus-Host Disease Prophylaxis in Related and Unrelated Donor Reduced-Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation  by Alyea, Edwin P. et al.
Sirolimus, Tacrolimus, and Low-Dose Methotrexate as
Graft-versus-Host Disease Prophylaxis in Related and
Unrelated Donor Reduced-Intensity Conditioning
Allogeneic Peripheral Blood Stem Cell Transplantation
Edwin P. Alyea,1 Shuli Li,2 Haesook T. Kim,2 Corey Cutler,1 Vincent Ho,1 Robert J. Soiffer,1 Joseph H. Antin1
1Medical Oncology and 2Biostatistical Science and Computational Biology, Dana-Farber Cancer Institute, Boston,
Massachusetts
Correspondence and reprint reequests to: Edwin Alyea, MD, Medical Oncology, Dana-Farber Cancer Institute,
44 Binney Street, D1B22, Boston, MA 02115 (e-mail: Edwin_alyea@dfci.harvard.edu).
Received December 31, 2007; accepted May 30, 2008
ABSTRACT
We assessed the combination of sirolimus, tacrolimus, and low-dose methotrexate as acute graft-versus-host
disease (aGVHD) prophylaxis after reduced-intensity conditioning (RIC) allogeneic peripheral blood stem
cell (PBSC) transplantation from matched related (MRD, n 5 46) and unrelated (URD, n 5 45) donors. All pa-
tients received fludarabine and intravenous busulfan conditioning followed by transplantation of mobilized
PBSC. The median time to neutrophil engraftment was 13 days. The cumulative incidence of grade II-IV and
III-IV aGVHD were 16% and 7%, respectively. There was no difference in the incidence of aGVHD between
MRD and URD cohorts. Two-year cumulative incidence of extensive chronic GVHD (cGVHD) was 40%. Re-
lapse-free survival (RFS) at 2 years was 34%: 21% inMRD and 45% in URD. Overall survival (OS) at 2 years was
59%: 47% inMRD and 67% in URD. High levels (.90%) of donor derived hematopoiesis were achieved in 59%
of patients early after transplantation. The addition of sirolimus to tacrolimus and low-dose methotrexate as
GVHD prophylaxis following RIC with fludarabine and low-dose intravenous busulfan is associated with rapid
engraftment, low rates of aGVHD, and achievement of high levels of donor chimerism.
 2008 American Society for Blood and Marrow Transplantation
KEY WORDS
Transplantation  Sirolimus  Reduced-intensity conditioning
Biology of Blood and Marrow Transplantation 14:920-926 (2008)
Q 2008 American Society for Blood and Marrow Transplantation
1083-8791/08/1408-0001$32.00/0
doi:10.1016/j.bbmt.2008.05.024INTRODUCTION
The development of acute graft-versus-host dis-
ease (aGVHD) remains a barrier to successful alloge-
neic reduced-intensity conditioning (RIC) peripheral
blood stem cell (PBSC) transplantation. A variety of
regimens to prevent the development of aGVHD
have been explored, and an optimal regimen has yet
to be defined. A calcineurin-inhibitor combined with
either methotrexate or mycophenolate mofetil is com-
monly used [1,2]. Other prophylaxis regimens have in-
cluded the use of anti-T cell-specific antibodies such as
antithymocyte globulin (ATG) or alemtuzumab [3,4].
Given the need to balance the prevention of aGVHD
with maintaining the graft-versus-malignancy effect,
which is the curative aspect of RIC transplantation, it
is important that regimens prevent GVHD while not920eliminating or reducing the graft-versus-malignancy
effect.
Sirolimus is an inhibitor of the mammalian target
of Rapamycin (mTOR). Sirolimus binds to FK bind-
ing protein 12 (FKBP12), forming a complex with
mTOR and the raptor/rictor proteins [5,6]. This siro-
limus-FKBP12-mTOR complex inhibits several path-
ways, resulting in a reduction in DNA transcription,
DNA translation, protein synthesis, and cell cycling,
resulting in T cell immunosuppression and impair-
ment of dendritic cell function. Moreover, in experi-
mental models, sirolimus results in an expansion of
CD41CD251FoxP3 regulatory T cells and does not
impair graft-versus leukemia (GVL) [7-9].
Sirolimus and calcineurin inhibitors agents work
synergistically [10], and have been used to prevent
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geneic stem cell transplantation. The combination of
sirolimus, tacrolimus, and low-dose methotrexate has
been demonstrated to be effective GVHD prophylaxis
in HLA-matched and partially mismatched URD
transplantation [11]. Sirolimus and tacrolimus without
methotrexate also have been used successfully to pre-
vent aGVHD in both matched related donors
(MRD) and unrelated donor (URD) myeloablative
allogeneic PBSC transplantation [12,13]. In this
report, we demonstrate the effectiveness of combining
sirolimus, tacrolimus, and low-dose methotrexate as
prophylaxis against aGVHD for patients receiving
RIC allogeneic transplantation from MRD or URD
for the treatment of hematologic malignancies.
METHODS
Study Design
Patients with hematologic malignancies receiving
unmanipulated HLA matched allogeneic transplanta-
tion from MRD or URD were eligible. Transplanta-
tion eligibility requirements included ECOG
performance status 0-2, absence of uncontrolled infec-
tion at the time of study entry, left ventricular ejection
fraction .30%, and normal or near-normal parame-
ters of kidney and liver function. All patients receiving
RIC were evaluated for myeloablative transplantation
and considered to have contraindications to that
approach. Relative contraindications to myeloablative
transplantation included prior myeloablative trans-
plantation, age .50 years, or significant organ
dysfunction. The Human Subjects Protection Com-
mittee of Dana-Farber Cancer Institute approved
investigational protocols. Written informed consent
was obtained in all cases.
All donors included in this analysis were HLA
matched at A, B, and DR loci. URD were required
to match recipients at HLA-DR loci by molecular
analysis. Class II typing was performed with se-
quence-specific oligonucleotide probes (SSOP). All
patients received filgrastim-mobilized PBSC. Donors
were mobilized with filgrastim at 10 mg/kg/day for 5
days. Stem cell collection was initiated on the fifth
day of filgrastim and continued until a sufficient num-
ber of CD341 cells were obtained. Target cell dose
was 1 2 107 CD341 cells/kg. PBSCs were mobilized
from URD according to local donor center practices.
The first day of stem cell infusion corresponded to
day 0.
Study Therapy
Patients received fludarabine (30 mg/m2/day on
days 26, 25, 24, 23) and intravenous busulfan (0.8
mg/kg/day on days 26, 25, 24, 23). Tacrolimus
was administered by mouth at 0.05 mg/kg/day starting
on day 23 with a target serum concentration of 5-10ng/mL. Sirolimus was administered as a 12-mg oral
loading dose on day23, followed by a 4-mg/day single
dose, with a target serum concentration of 3-12 ng/mL
by HPLC. Methotrexate was administered at 5 mg/m2
intravenously days 1, 3, and 6 after transplantation.
Filgrastim was administered at 5 mg/kg/day beginning
on day 11, and was continued until neutrophil en-
graftment. Patients received prophylactic antiviral
therapy against herpes virus infections and prophylaxis
against Pneumocystis carinii. No prophylactic antifungal
therapy was administered. All patients were monitored
for CMV reactivation, without prophylactic therapy.
Acute GVHD was graded according to the consensus
grading scale [14]. If a patient developed evidence of
recurrent disease, taper of the immune suppression
was at the discretion of the treating physician.
Chimerism Analysis
Unfractionated donor chimerism was assessed
from bone marrow aspirates at approximately day
130-45 posttransplant. Genotype of donor and recip-
ient were determined using DNA extracted from pre-
transplant samples. Nine short tandem repeat (STR)
loci were typed using the ABI Profiler Plus Kit (Ap-
plied Biosystems Inc., Foster City, CA) and the ABI
310 Genetic Analyzer to resolve alleles. ‘‘Informative’’
alleles that were present only in the donor or recipient
were used in the chimerism calculations. In cases of
gender mismatched donor-recipient pairs where mo-
lecular chimerism analysis was not available, assess-
ment of donor chimerism was based on fluorescent
in situ hybridization (FISH) for X and Y chromo-
somes, or cytogenetic analysis.
Statistical Analysis
Descriptive statistics was provided for patient
baseline characteristics. Two-sided Fisher’s exact test
was used to compare incidence of GVHD, and 2-sided
Wilcoxon-Rank-Sum test was used for 2-sample com-
parison of number of stem cells infused and time to en-
graftment.
Cumulative incidence curves for aGVHD, chronic
GVHD (cGVHD), and relapse were constructed re-
flecting early death, death and relapse, and nonrelapse
treatment-related death as competing risks, respec-
tively [15]. Time to relapse and time to treatment-
related death were measured from the date of stem
cell infusion. Patients who were alive without relapse
were censored at the time last seen alive. Overall sur-
vival (OS) and relapse-free survival (RFS) were calcu-
lated using the Kaplan-Meier method. OS was
defined as the time from stem cell infusion to death
from any cause. Elapse-free survival (EFS) was defined
as the time from stem cell infusion to relapse or death
from any cause. The Log-Rank test was used for group
comparisons of OS or RFS. Prognostic factors for OS
922 E. P. Alyea et al.and RFS were examined in the Cox proportional haz-
ards model.
RESULTS
Patient Characteristics
The characteristics of all 91 patients are detailed in
Table 1. Forty-five patients (49%) had an unrelated
donor and 46 patients (51%) had a related donor.
Thirty-seven patients (41%) had AML or MDS, and
these diagnoses were the most common indication
for transplantation. Low-risk disease was defined as
acute leukemia in first complete remission (CR1), de
novo early stage myelodysplastic syndrome (RA or
RARS), and first chronic phase CML. Seventeen pa-
tients (19%) had low-risk disease and 74 patients
(81%) had advanced-stage disease at the time of trans-
plantation. The median age was 57 years (range: 20 to
69 years). Thirty-two patients (35%) had undergone
prior myeloablative transplantation. The median fol-
low-up for those still alive is 24 months (range: 3.4
to 44 months).
Stem Cell Product and Engraftment
All patients received unmanipulated PBSC. The
median number of CD341 cells infused was 8.6 
106 CD341 cells/kg (range: 2.4  106 to 29  106).
Table 1. Baseline Characteristics
Sample size 91
Median age (range) 57 (20, 69)
Sex
Male 62 (68%)
Female 29 (32%)
Gender mismatch (donor/recipient)
M/M, F/F 46 (50%)
F/M, M/F 45 (50%)
Disease
AML 24 (26%)
CR1 10
.CR1 14
CML 7 (8%)
CP 5
AP/BC 2
CLL 17 (19%)
NHL 18 (20%)
HD 6 (7%)
MDS 13 (15%)
RA/RARS 5
RAEB/RAEBT 8
Myeloproliferative diseases 3 (3%)
ALL/.CR 1 1 (1%)
Plasma cell dyscrasia 2 (2%)
Prior transplantation 32 (35%)
Remission status at time of transplant
Complete remission/first chronic phase 27 (30%)
Active disease 64 (70%)
Risk status
High risk 74 (81%)
Low risk 17 (19%)URD received a median of 9.5  106 CD341 cells/
kg (range: 2.4  106 to 29  106), which was statisti-
cally higher than MRD recipients with a median of
7.8  106 CD341 cell/kg (range: 2.5  106 to 19 
106) (P 5 .02).
All patients engrafted. The majority of patients
(52%) did not develop neutropenia (ANC\500). Of
the 44 patients who did develop neutropenia or who
were neutropenic prior to receiving the conditioning
regimen, the median time to neutrophil recovery (de-
fined as day to absolute neutrophil count .500) was
13 days (range: 3 to 32). There were no significant dif-
ferences in the time to engraftment of MRD and URD
donors. Donor-derived hematopoiesis was assessed at
day 30 to 45 after transplantation. By day 45, 89% of
patients had achieved .50% donor derived hemato-
poiesis with 59% of all patients achieving .90% do-
nor-derived hematopoiesis.
Acute GVHD and cGVHD
In a competing risk model, the cumulative inci-
dence of grade II-IV aGVHD was 10% by day 100
and 16% by day 200 posttransplantation (Figure 1).
Of the 14 patients developing grade 2-4 aGVHD, 8
(9%) developed grade 2 aGVHD, and 6 patients
(7%) developed grade 3-4 aGVHD.Therewas a differ-
ence in incidence of aGVHD between MRD (11%)
and URD (20%) cohorts; however, this difference
was not statistically significant (P 5 .22). Eight
patients were mismatched at HLA-C (7 URD, 1
MRD). One of these 8 patients developed grade II
aGVHD.
Two-year cumulative incidence of extensive
cGVHD was 40%. There was a trend for a higher in-
cidence of extensive cGVHD in recipients of URD
transplantation (49%) compared with recipients of
MRD transplantation (30%) (P 5 .06). The median
time to onset was 6.5 months (range: 3-12 months).
The majority of patients developed de novo cGVHD
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Figure 1. Cumulative index of grade 2-4 aGVHD after transplanta-
tion.MRD, matched related donor; URD, unrelated donor.
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from aGVHD to cGVHD (19%). There was no corre-
lation between the development of aGVHD and the
development of cGVHD.
Survival and Outcome
Nonrelapse mortality (NRM) at 100 days was 1%.
Two-year cumulative incidence of treatment-related
mortality was 6%.Nonrelapse causes of treatment fail-
ure included GVHD (1), infection (2), and pulmonary
toxicity (3) (Table 2). No patients developed VOD or
evidence of TTP/HUS. The primary cause for treat-
ment failure was relapse of disease. OS estimates at
1 and 2 years are 74% and 59%, respectively
(Figure 2a). RFS after transplantation at 1 and 2 years
are 47% and 34%, respectively (Figure 2b). Although
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Figure 2. (A) Overall survival. (B) Relapse-free survival.
Table 2. Cause of Treatment Failure
Cause of Treatment Failure N
Relapse 34 (77%)
GVHD 1 (2%)
Infection 2 (5%)
Idiopathic pneumonia syndrome 3 (7%)theURD cohort showed superiorOS and RFS, neither
was statistically significantly different (P5 .37, P5 .1,
respectively). The cumulative incidence of relapse at 2
years is 60%. The cumulative risk of relapse for patient
with URD was 42% compared with 73% for patients
with MRD, but this difference does not reach statisti-
cal significance (P 5 .09) (Figure 3).
Factors Associated with Outcome and Toxicity
Cox regression analysis was performed to identify
factors associated with OS, RFS, and treatment-re-
lated mortality. Factors analyzed included age, pa-
tient-donor sex mismatch, donor type (related versus
unrelated), history of a prior transplant, risk status at
time of transplantation, recipient CMV status, number
of CD34 cells infused, and day 30-45 chimerism. Pa-
tients with positive CMV status had a shorter OS (haz-
ard ratio [HR] 5 2.1, P 5 .06). Patients receiving
a higher dose of CD341 cells (.5  106 CD341
cells/kg) had an improved RFS (HR 5 0.43, P 5 .02)
but not OS. No other factors including chimerism
were found to be significant.
DISCUSSION
The development of aGVHD after RIC transplan-
tation contributes to transplant-related morbidity
(TRM) and mortality, as well as prevents the adminis-
tration of posttransplant immune therapies for patients
with persistent disease. Although initially hypothesized
that the incidence of aGVHD would be lower after
nonmyeloablative regimens because of less tissue dam-
age resulting in lack of pro-inflammatory cytokines,
the incidence of aGVHD after RIC transplantation
remains significant. Two strategies have been pursued
to prevent the development of aGVHD; pharmaco-
logic prophylaxis often using calcineurin inhibitors,
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Figure 3. Cumulative incidence of relapse with treatment related
mortality as a competing risk. MRD, matched related donor;
URD, unrelated donor; TRM, treatment-related mortality.
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antibodies such as ATG or alemtuzumab or cell sepa-
ration technologies. In RIC transplantation defining
the correct balance between controlling GVHD by
suppression of T cell function and preserving GVL
activity is critical because the success of RIC transplan-
tation is based on the preservation of theGVLeffect. In
the current report, we used a potent immunosuppres-
sive agent, sirolimus, combined with tacrolimus and
low-dose methotrexate and demonstrate low rates of
aGVHD for both MRD and URD after receiving
RIC allogeneic PBCS transplantation.
Sirolimus has been effective in reducing the
incidence of aGVHD after myeloablative stem cell
transplantation. When combined with low-dose
methotrexate, sirolimus improved GVHD control in
patients receiving transplantation from mismatched
related andURD [11]. Sirolimus combined with tacro-
limus without the use of methotrexate also results in
excellent prevention of aGVHD in both MRD and
URD myeloablative stem cell transplantation, and is
associated with a low treatment-related mortality
[13]. A randomized trial comparing tacrolimus and si-
rolimus as GVHD prophylaxis with tacrolimus and
methotrexate in patients undergoing matched related
myeloablative transplantation is currently underway
to confirm these findings. An increased risk of VOD
has been noted in patients receiving sirolimus as
GVHD after myeloablative transplantation [16]. In
the current study, no patients developed VOD or
TTP/HUS. This suggests that the endothelial or
other tissue damage mediated by myeloablative condi-
tioning in the setting of sirolimus administration is
needed to predispose to VOD.
The incidence of aGVHD noted in this study of
RIC compares favorably with other pharmacologic
prophylactic strategies of GVHD after RIC transplan-
tation. Rates for developing aGVHD for patients re-
ceiving cyclosporine and MMF range from 16% to
47% for related donors [17,18] and in reports of
URD transplantation up to52% [19]. Reports have
suggested that cyclosporine and MMFmay not be suf-
ficient to prevent GVHD in URD [20]. Rates for de-
veloping aGVHD after RIC transplantation using
tacrolimus or cyclosporine and methotrexate range
from 12% to 36% for patients with related and URD
[21,22]. Incorporation of alemtuzumab asGVHDpro-
phylaxis is associated with a low incidence of aGVHD
and cGVHD [4]; however, many patients have persis-
tent or progressive disease after transplantation sug-
gesting that some element of the GVL effect has
been compromised.
Sirolimus, in addition to its immune suppressive
properties that prevent aGVHD, has several potential
advantages including possible antitumor activity, and
may facilitate engraftment of donor cells. Sirolimus
has been identified as having direct antitumor activityin several hematologic malignancies [23]. Antitumor
activity has been demonstrated in vitro in AML,
CLL, multiple myeloma, and lymphoma [24-29].
The antileukemic activity of rapamycin appears to be
mediated through inhibition of the mTOR pathway
and inhibits immature cells by blockade in the G0/
G1 phase of the cell cycle. Demonstrating in vivo ac-
tivity, 4 of 9 patients with refractory/relapsed AML
demonstrated significant clinical responses following
treatment with sirolimus [30]. Preliminary results in-
corporating sirolimus into a RIC regimen in a group
of patients with high-risk leukemia suggested im-
proved disease control after transplant [31]. In the cur-
rent study, despite the use of sirolimus, relapse of
disease remains the principle reason for treatment fail-
ure. It is unclear if the doses used to prevent aGVHD
are sufficient to mediate antitumor activity. Larger se-
ries will be needed to assess the impact of sirolimus on
disease control in specific diseases.
High levels of donor-derived hematopoeisis early
after RIC transplantation were noted in patients in
this trial. Several studies have demonstrated that high
levels of donor-derived hematopoiesis predict im-
proved outcome for certain patient populations after
RIC transplantation [32-34]. Preclinical data suggests
that sirolimus combined with cyclosporine facilitates
stable mixed chimerism in animals given sublethal to-
tal-body irradiation (TBI) [35,36] and facilitates the
development of tolerance in a mismatched rodent
stem cell transplant model [37]. Comparison of siroli-
mus containing GVHD prophylactic regimens with
other regimens is needed to see if the addition of siro-
limus augments donor chimerism, and if this can be
translated into improved outcome.
Patients receiving transplantation from a URD
had a marginally improved RFS (P 5 .1) when com-
pared with patients receiving transplantation from an
MRD. This observation is consistent with other publi-
cations of RIC transplantation [38]. Presumably the
increased genetic disparity between donor and host
may also facilitate greater donor-versus-malignancy
effect. With improved control of aGVHD and result-
ing reduction in treatment-related mortality associ-
ated with URD transplantation, the impact of donor
source on disease control is now recognizable.
Sirolimus, when combined with tacrolimus and
low-dose methotrexate, provide adequate prophylaxis
against the development of aGVHD in patients under-
going RIC PBSC transplantation from related and
URD. This combination was safe and well tolerated
in a patient population that was at high risk for compli-
cations after transplantation. Given that sirolimus has
several properties that may be advantageous when used
after RIC transplantation, such as antitumor activity
and facilitation of chimerism, this agent when used
in combination with other agents should be compared
with other GVHD prophylactic regimens.
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